Please Wait.....
Report
Liver Disease Treatments: The Global Market
Market Research Report I 2025-04-22 I 164 Pages I BCC Research
Description
Report Scope:
This report on the global market for liver disease treatments provides qualitative and quantitative data on the current market dynamics. It discusses different liver diseases and their treatment modalities.
Analyses of the most frequently used products, clinical trials, new product approvals, and emerging technologies are also included. The demographics of the major regions-North America, Europe, Asia-Pacific, South America, and the Middle East and Africa-as well as their prospects for growth are summarized. The profiles of leading companies in the market and their strategies are also discussed.
The market for liver disease treatments is broken into hepatitis, non-alcoholic fatty liver disease (NAFLD), hepatocellular carcinoma, autoimmune liver diseases, alcohol-induced liver disease (ALD), chronic liver disease, and others. The growth potential and forecast data are discussed for each disease for the aforementioned regions and many countries.
The report includes global revenue in $ millions for the base year of 2024, estimates for 2025, and data for the forecast period of 2026 through 2030.
Report Includes :
- 52 data tables and 63 additional tables
- Analyses of the trends in the global markets for liver disease treatments, with revenue data from 2023, estimates for 2024, forecasts for 2025, and projected CAGRs through 2029
- Estimates of the size and revenue prospects for the global market, along with a market share analysis by product (drug) type, disease type, route of administration, end user, and region
- Facts and figures pertaining to market dynamics, opportunities and deterrents, technological advances, regulations, and the impacts of macroeconomic variables
- Insights derived from the Porter's Five Forces model, as well as global supply chain and PESTLE analyses
- An assessment of the major drugs that can cause liver disease, the market's current situation and future prospects, clinical trials, new developments, and pipeline products
- An analysis of the key patent grants and recently published patents
- Overview of the sustainability trends and ESG developments in the industry, with emphasis on the ESG practices followed by leading companies, their ESG ratings, and consumer attitudes
- Analysis of the industry structure, including companies' product offerings, strategic alliances, M&A activity, venture fundings and investment outlook
- Company profiles of major players within the industry, including Gilead Sciences Inc., Bristol Myers Squibb Co., AbbVie Inc., and Merck & Co. Inc.
Executive Summary
Summary:
The global market for liver disease treatments is estimated to increase from $46.0 billion in 2024 to reach $69.1 billion by 2030, at a compound annual growth rate (CAGR) of 7.1% from 2025 through 2030.
Liver diseases, which include cirrhosis, viral hepatitis and liver cancer, are responsible for more than 2 million deaths annually worldwide, or about 4% of all deaths (Devarbhavi H; et al.; Journal of Hepatology; 2023). An estimated 1 million people die each year from chronic liver disease and the cirrhosis it causes, and 600,000 to 900,000 die from liver cancer. Liver disease is the 11th most common cause of death worldwide, and the 15th most common cause of life years with a disability
The global market for liver disease treatments was valued at $46.0 billion in 2024 and is expected to reach $69.1 billion by the end of 2030, at a compound annual growth rate (CAGR) of 7.1% for the forecast period. Leading pharmaceutical companies in the liver disease treatment market include -
- Gilead Sciences: Known for its portfolio of hepatitis C treatments (e.g., Sovaldi, Harvoni) andongoing work in non-alcoholic steatohepatitis (NASH) treatments.
- Bristol Myers Squibb: Active in the hepatitis market and liver cancer treatments with drugs like Opdivo and Yervoy.
- AbbVie: Its hepatitis C treatment, Mavyret, is one of the leading drugs on the market.
- Merck & Co.: Developing immunotherapies for liver cancer and also involved in hepatitis B treatments.
Biotechnology firms developing novel therapies for liver disorders, particularly those like liver fibrosis and NASH, are also showing interest in the market.
Table of Contents
Chapter 1 Executive Summary
Market Outlook
Scope of Report
Market Summary
Chapter 2 Market Overview
Overview
Classification of Therapies, by Disease and Product
Hepatitis
Liver Tumors and Liver Cancer
Autoimmune Liver Diseases
Alcohol-induced liver disease
Chronic Liver Disease
Non-Alcoholic Fatty Liver Disease
Analysis of Macroeconomic Factors
Population Demographics and Aging Population
Global Economic Growth
Geopolitical Risks, Trade Wars, and Supply Chain Disruptions
Public Awareness and Education
Porter's Five Forces
Potential for New Entrants (Moderate to Low)
Bargaining Power of Suppliers (Moderate to High)
Bargaining Power of Buyers (Moderate to High)
Threat of Substitute Products or Services (Low to Moderate)
Industry Competitiveness (High)
Chapter 3 Market Dynamics
Overview
Market Drivers
Increasing Incidence of Liver Diseases
Consumption of Alcohol and Improper Diet
Government Initiatives to Provide Vaccines and Grow Awareness
Market Restraints
FDA Approvals and Stringent Government Regulations
Side Effects and Risks Associated with Drugs
Market Opportunities
Advances in Treatment Options
Emerging Markets and Access to Treatment
Chapter 4 Regulatory Landscape
Global Regulatory Agencies
U.S. Food and Drug Administration
European Medicines Agency
Japan's Pharmaceuticals and Medical Devices Agency
China's National Medical Products Administration
Considerations in Liver Drug Development
Chapter 5 Emerging Trends and Pipeline Analysis
Emerging Trends
Personalized Medicine in Liver Disease
Advances in Liver Transplantation
Regenerative Medicine and Stem Cell Therapy
Immunotherapy for Liver Cancer
Repairing Liver Disease with mRNA
Pipeline Analysis
Patent Analysis
Findings
Chapter 6 Market Segmentation Analysis
Segmentation Breakdown
Market Breakdown, by Disease Type
Takeaways
Hepatitis
Non-Alcoholic Fatty Liver Disease
Hepatocellular Carcinoma
Autoimmune Liver Diseases
Alcohol-induced Liver Disease (ALD)
Chronic Liver Disease
Other Liver-Related Diseases
Geographic Breakdown
Market Breakdown, by Region
Takeaways
North America
Europe
Asia-Pacific
South America
Middle East and Africa
Chapter 7 Competitive Intelligence
Takeaways
Market Ranking of Leading Companies
Strategic Analysis
Venture Funding and Investments
Chapter 8 Sustainability in the Liver Disease Treatment Industry: ESG Perspective
Overview
Environmental Sustainability
Social Responsibility (S)
Governance
ESG Risk Ratings
Concluding Remarks from BCC
Chapter 9 Appendix
Research Methodology
Sources
Abbreviations
Company Profiles
ABBVIE INC.
ASTRAZENECA
BAYER AG
BIOTEST AG
BRISTOL-MYERS SQUIBB CO.
F. HOFFMANN-LA ROCHE LTD.
GILEAD SCIENCES INC.
GSK PLC.
INTERCEPT PHARMACEUTICALS INC.
MADRIGAL PHARMACEUTICALS
MERCK & CO. INC.
NOVARTIS AG
SALIX PHARMACEUTICALS
SANOFI
TAKEDA PHARMACEUTICAL CO. LTD.
Emerging Start-ups/Market Disruptors
List of Tables
Summary Table : Global Market for Liver Disease Treatments, by Region, Through 2030
Table 1 : Vaccines for Preventing Hepatitis A and B
Table 2 : Drugs Used to Treat Autoimmune Liver Diseases
Table 3 : Porter's Five Forces: Rating Scale
Table 4 : Estimates of the Burden of Chronic Hepatitis B and C, by WHO Region, 2022
Table 5 : Possible Side Effects of Liver Treatment Drugs
Table 6 : FDA Drug Approvals for Liver Treatment, 2022-2024
Table 7 : EMA Drug Approvals for Liver Treatment, 2024 and 2025
Table 8 : Drugs Approved by the PMDA for Liver Treatment, 2022-2024
Table 9 : Pipeline Drugs for Liver Disease Treatment in Phases 3 and 4, 2024
Table 10 : Granted Patents in Liver Drugs, 2023-2025
Table 11 : Global Market for Liver Disease Treatments, by Disease Type, Through 2030
Table 12 : Global Market for Treatments for Hepatitis, by Region, Through 2030
Table 13 : Pipeline Drugs for NAFLD
Table 14 : Global Market for Treating NAFLD, by Region, Through 2030
Table 15 : Countries with Highest Incidence of Liver Cancer, 2022
Table 16 : Global Market for Treating Hepatocellular Carcinoma, by Region, Through 2030
Table 17 : Global Market for Treating Autoimmune Liver Diseases, by Region, Through 2030
Table 18 : Global Market for Treating Alcohol-induced Liver Disease, by Region, Through 2030
Table 19 : Global Market for Treating Chronic Liver Disease, by Region, Through 2030
Table 20 : Global Market for Treating Other Liver Diseases, by Region, Through 2030
Table 21 : Global Market for Liver Disease Treatments, by Region, Through 2030
Table 22 : North American Market for Liver Disease Treatments, by Disease Type, Through 2030
Table 23 : North American Market for Liver Disease Treatments, by Country, Through 2030
Table 24 : U.S. Market for Liver Disease Treatments, by Disease Type, Through 2030
Table 25 : Canadian Market for Liver Disease Treatments, by Disease Type, Through 2030
Table 26 : Liver Transplants from Donors, Per Center in Mexico, in 2023
Table 27 : Mexican Market for Liver Disease Treatments, by Disease Type, Through 2030
Table 28 : European Market for Liver Disease Treatments, by Disease Type, Through 2030
Table 29 : European Market for Liver Disease Treatments, by Country, Through 2030
Table 30 : German Market for Liver Disease Treatments, by Disease Type, Through 2030
Table 31 : Premature Mortality Due to Alcoholic Liver Disease, 2019, 2022, 2023
Table 32 : U.K. Market for Liver Disease Treatments, by Disease Type, Through 2030
Table 33 : French Market for Liver Disease Treatments, by Disease Type, Through 2030
Table 34 : Spanish Market for Liver Disease Treatments, by Disease Type, Through 2030
Table 35 : Italian Market for Liver Disease Treatments, by Disease Type, Through 2030
Table 36 : Rest of European Market for Liver Disease Treatments, by Disease Type, Through 2030
Table 37 : Asia-Pacific Market for Liver Disease Treatments, by Disease Type, Through 2030
Table 38 : Asia-Pacific Market for Liver Disease Treatments, by Country, Through 2030
Table 39 : Chinese Market for Liver Disease Treatments, by Disease Type, Through 2030
Table 40 : Japanese Market for Liver Disease Treatments, by Disease Type, Through 2030
Table 41 : Indian Market for Liver Disease Treatments, by Disease Type, Through 2030
Table 42 : Rest of Asia-Pacific Market for Liver Disease Treatments, by Disease Type, Through 2030
Table 43 : South American Market for Liver Disease Treatments, by Disease Type, Through 2030
Table 44 : South American Market for Liver Disease Treatments, by Country, Through 2030
Table 45 : Brazilian Market for Liver Disease Treatments, by Disease Type, Through 2030
Table 46 : Argentinian Market for Liver Disease Treatments, by Disease Type, Through 2030
Table 47 : Rest of South American Market for Liver Disease Treatments, by Disease Type, Through 2030
Table 48 : MEA Market for Liver Disease Treatments, by Disease Type, Through 2030
Table 49 : MEA Market for Liver Disease Treatments, by Region, Through 2030
Table 50 : Middle East Market for Liver Disease Treatments, by Disease Type, Through 2030
Table 51 : African Market for Liver Disease Treatments, by Disease Type, Through 2030
Table 52 : Leading Companies in the Market for Liver Disease Treatments, 2024
Table 53 : Recent Venture Funding in the Liver Disease Treatment Industry
Table 54 : ESG Risk Rankings for Pharmaceutical Firms in the Liver Disease Market
Table 55 : Report Information Sources
Table 56 : Abbreviations Used in the Report
Table 57 : AbbVie Inc.: Company Snapshot
Table 58 : AbbVie Inc.: Financial Performance, FY 2023 and 2024
Table 59 : AbbVie Inc.: Product Portfolio
Table 60 : AstraZeneca: Company Snapshot
Table 61 : AstraZeneca: Financial Performance, FY 2023 and 2024
Table 62 : AstraZeneca: Product Portfolio
Table 63 : AstraZeneca: News/Key Developments, 2022 and 2023
Table 64 : Bayer AG: Company Snapshot
Table 65 : Bayer AG: Financial Performance, FY 2023 and 2024
Table 66 : Bayer AG: Product Portfolio
Table 67 : Bayer AG: News/Key Developments, 2023 and 2024
Table 68 : Biotest AG: Company Snapshot
Table 69 : Biotest AG: Financial Performance, FY 2023 and 2024
Table 70 : Biotest AG: Product Portfolio
Table 71 : Biotest AG: News/Key Developments, 2023
Table 72 : Bristol-Myers Squibb Co.: Company Snapshot
Table 73 : Bristol-Myers Squibb Co.: Financial Performance, FY 2023 and 2024
Table 74 : Bristol-Myers Squibb Co.: Product Portfolio
Table 75 : Bristol-Myers Squibb Co.: News/Key Developments, 2025
Table 76 : F. Hoffmann-La Roche Ltd.: Company Snapshot
Table 77 : F. Hoffmann-La Roche Ltd.: Financial Performance, FY 2023 and 2024
Table 78 : F. Hoffmann-La Roche Ltd.: Product Portfolio
Table 79 : F. Hoffmann-La Roche Ltd.: News/Key Developments, 2023
Table 80 : Gilead Sciences Inc.: Company Snapshot
Table 81 : Gilead Sciences Inc.: Financial Performance, FY 2023 and 2024
Table 82 : Gilead Sciences Inc.: Product Portfolio
Table 83 : Gilead Sciences Inc.: News/Key Developments, 2024
Table 84 : GSK plc.: Company Snapshot
Table 85 : GSK plc.: Financial Performance, FY 2023 and 2024
Table 86 : GSK plc.: Product Portfolio
Table 87 : GSK plc.: News/Key Developments, 2024
Table 88 : Intercept Pharmaceuticals Inc.: Company Snapshot
Table 89 : Intercept Pharmaceuticals Inc.: Product Portfolio
Table 90 : Intercept Pharmaceuticals Inc.: News/Key Developments, 2024
Table 91 : Madrigal Pharmaceuticals: Company Snapshot
Table 92 : Madrigal Pharmaceuticals: Financial Performance, FY 2023 and 2024
Table 93 : Madrigal Pharmaceuticals: Product Portfolio
Table 94 : Madrigal Pharmaceuticals: News/Key Developments, 2024
Table 95 : Merck & Co. Inc.: Company Snapshot
Table 96 : Merck & Co. Inc.: Financial Performance, FY 2023 and 2024
Table 97 : Merck & Co. Inc.: Product Portfolio
Table 98 : Merck & Co. Inc.: News/Key Developments, 2024
Table 99 : Novartis AG: Company Snapshot
Table 100 : Novartis AG: Financial Performance, FY 2023 and 2024
Table 101 : Novartis AG: Product Portfolio
Table 102 : Novartis AG: News/Key Developments, 2022
Table 103 : Salix Pharmaceuticals: Company Snapshot
Table 104 : Salix Pharmaceuticals: Product Portfolio
Table 105 : Salix Pharmaceuticals: News/Key Developments, 2023
Table 106 : Sanofi: Company Snapshot
Table 107 : Sanofi: Financial Performance, FY 2023 and 2024
Table 108 : Sanofi: Product Portfolio
Table 109 : Sanofi: News/Key Developments, 2024
Table 110 : Takeda Pharmaceutical Co. Ltd.: Company Snapshot
Table 111 : Takeda Pharmaceutical Co. Ltd.: Financial Performance, FY 2022 and 2023
Table 112 : Takeda Pharmaceutical Co. Ltd.: Product Portfolio
Table 113 : Takeda Pharmaceutical Co. Ltd.: News/Key Developments, 2023 and 2024
Table 114 : Emerging Startups
List of Figures
Summary Figure : Shares of Global Market for Liver Disease Treatments, by Region, 2024
Figure 1 : Porter's Five Forces Analysis
Figure 2 : Market Dynamics of Liver Disease Treatments
Figure 3 : Distribution of Death by Liver Diseases in England, by Age Group, 2020
Figure 4 : Clinical Trial Studies of Liver Treatment Drugs, by Trial Phase, 2024
Figure 5 : Patent Analysis of Liver Treatment Drugs, 2022-2025
Figure 6 : Shares of Global Market for Liver Disease Treatments, by Disease Type, 2024
Figure 7 : Shares of Global Market for Hepatitis Treatments, by Region, 2024
Figure 8 : Shares of Global Market for Treating NAFLD, by Region, 2024
Figure 9 : Shares of Global Market for Treating Hepatocellular Carcinoma, by Region, 2024
Figure 10 : Shares of Global Market for Treating Autoimmune Liver Diseases, by Region, 2024
Figure 11 : Shares of Global Market for Treating Alcohol-induced Liver Disease, by Region, 2024
Figure 12 : Shares of Global Market for Treating Chronic Liver Disease, by Region, 2024
Figure 13 : Shares of Global Market for Treating Other Liver Diseases, by Region, 2024
Figure 14 : Shares of Global Market for Liver Disease Treatments, by Region, 2024
Figure 15 : Shares of North American Market for Liver Disease Treatments, by Disease Type, 2024
Figure 16 : Shares of North American Market for Liver Disease Treatments, by Country, 2024
Figure 17 : Shares of U.S. Market for Liver Disease Treatments, by Disease Type, 2024
Figure 18 : Shares of Canadian Market for Liver Diseases Treatments, by Disease Type, 2024
Figure 19 : Shares of Mexican Market for Liver Disease Treatments, by Disease Type, 2024
Figure 20 : Shares of European Market for Liver Disease Treatments, by Disease Type, 2024
Figure 21 : Shares of European Market for Liver Disease Treatments, by Country, 2024
Figure 22 : Deaths Due to Chronic Liver Disease in Germany, 2011-2021
Figure 23 : Shares of German Market for Liver Disease Treatments, by Disease Type, 2024
Figure 24 : Shares of U.K. Market for Liver Disease Treatments, by Disease Type, 2024
Figure 25 : Shares of French Market for Liver Disease Treatments, by Disease Type, 2024
Figure 26 : Shares of Spanish Market for Liver Disease Treatments, by Disease Type, 2024
Figure 27 : Shares of Italian Market for Liver Disease Treatments, by Disease Type, 2024
Figure 28 : Shares of Rest of European Market for Liver Disease Treatments, by Disease Type, 2024
Figure 29 : Shares of Asia-Pacific Market for Liver Disease Treatments, by Disease Type, 2024
Figure 30 : Shares of Asia-Pacific Market for Liver Disease Treatments, by Country, 2024
Figure 31 : Shares of Chinese Market for Liver Disease Treatments, by Disease Type, 2024
Figure 32 : Shares of Japanese Market for Liver Disease Treatments, by Disease Type, 2024
Figure 33 : Shares of Indian Market for Liver Disease Treatments, by Disease Type, 2024
Figure 34 : Shares of Rest of Asia-Pacific Market for Liver Disease Treatments, by Disease Type, 2024
Figure 35 : Shares of South American Market for Liver Disease Treatments, by Disease Type, 2024
Figure 36 : Shares of South American Market for Liver Disease Treatments, by Country, 2023
Figure 37 : Shares of Brazilian Market for Liver Disease Treatments, by Disease Type, 2024
Figure 38 : Shares of Argentinian Market for Liver Disease Treatments, by Disease Type, 2024
Figure 39 : Shares of Rest of South American Market for Liver Disease Treatments, by Disease Type, 2024
Figure 40 : Shares of MEA Market for Liver Disease Treatments, by Disease Type, 2024
Figure 41 : Shares of MEA Market for Liver Disease Treatments, by Region, 2024
Figure 42 : Shares of Middle East Market for Liver Disease Treatments, by Disease Type, 2024
Figure 43 : Shares of African Market for Liver Disease Treatments, by Disease Type, 2024
Figure 44 : AbbVie Inc.: Revenue Shares, by Business Unit, FY 2024
Figure 45 : AbbVie Inc.: Revenue Shares, by Country/Region, FY 2024
Figure 46 : AstraZeneca: Revenue Shares, by Business Unit, FY 2024
Figure 47 : AstraZeneca: Revenue Shares, by Region/Country, FY 2024
Figure 48 : Bayer AG: Revenue Shares, by Business Unit, FY 2024
Figure 49 : Bayer AG: Revenue Shares, by Country/Region, FY 2024
Figure 50 : Biotest AG: Revenue Shares, by Business Unit, FY 2024
Figure 51 : Biotest AG: Revenue Shares, by Country/Region, FY 2024
Figure 52 : Bristol-Myers Squibb Co.: Revenue Shares, by Business Unit, FY 2024
Figure 53 : Bristol-Myers Squibb Co.: Revenue Shares, by Country/Region, FY 2024
Figure 54 : F. Hoffmann-La Roche Ltd.: Revenue Shares, by Business Unit, FY 2024
Figure 55 : F. Hoffmann-La Roche Ltd.: Revenue Shares, by Country/Region, FY 2024
Figure 56 : Gilead Sciences Inc.: Revenue Shares, by Business Unit, FY 2024
Figure 57 : Gilead Sciences Inc.: Revenue Shares, by Country/Region, FY 2024
Figure 58 : GSK plc.: Revenue Shares, by Business Unit, FY 2024
Figure 59 : GSK plc.: Revenue Shares, by Country/Region, FY 2024
Figure 60 : Merck & Co. Inc.: Revenue Shares, by Business Unit, FY 2024
Figure 61 : Merck & Co. Inc.: Revenue Shares, by Country/Region, FY 2024
Figure 62 : Novartis AG: Revenue Shares, by Business Unit, FY 2024
Figure 63 : Novartis AG: Revenue Shares, by Country/Region, FY 2024
Figure 64 : Sanofi: Revenue Shares, by Business Unit, FY 2024
Figure 65 : Sanofi: Revenue Shares, by Country/Region, FY 2024
Figure 66 : Takeda Pharmaceutical Co. Ltd.: Revenue Shares, by Business Unit, FY 2023
Figure 67 : Takeda Pharmaceutical Co. Ltd.: Revenue Shares, by Country/Region, FY 2023
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security